External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in japanese patients

Urologia Internationalis

Volumn 89, Issue 1, 2012, Pages 45-51

  Yoshida, Takahiro ^a   Nakayama, Masashi ^a   Takeda, Ken ^a   Arai, Yasuyuki ^a   Kakimoto, Ken Ichi ^a   Nishimura, Kazuo ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Biochemical relapse; CAPRA; Japanese patients; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; ARTICLE; CALIBRATION; CANCER LOCALIZATION; CANCER OF THE PROSTATE RISK ASSESSMENT SCORE; CANCER PATIENT; CANCER SURGERY; COHORT ANALYSIS; EXTERNAL VALIDITY; HUMAN; HUMAN TISSUE; JAPANESE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864601142     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000336924     Document Type: Article

References (17)

1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-523. (Pubitemid 36132976)
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597. (Pubitemid 29211767)
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Toma-szewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
4. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, Fearn PA, Kattan MW: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Ca ncer Inst 2006; 98: 715-717. (Pubitemid 43821789)
5. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR: The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-1942. (Pubitemid 40675216)
6. Cooperberg MR, Freedland SJ, Pasta DJ, El-kin EP, Presti JC Jr, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR: Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006; 107:2384-2391. (Pubitemid 44748521)
7. May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O: Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007; 178: 1957-1962. (Pubitemid 47538618)
8. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urolog y 2008; 72: 396-400.
9. Loeb S, Carvalhal GF, Kan D, Desai A, Catalona WJ: External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urol Oncol 2010, E-pub ahead of print.
10. Ohshima A, Kuroishi T, Tajima K: Cancer Statistics-Morbidity/Mortality/ Prognosis. Tokyo, Shinohara, 2004.
11. Cancer Registration Committee of the Japanese Urological Association: Clinicopatho-logical statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12:46-61.
12. Center for Cancer Control and Information Services, National Cancer Center (data in Japanese). http://ganjoho.jp/professional/statistics/statistics. html (accessed April 2011).
13. Cooperberg MR, Broering JM, Carroll PR: Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101:878-887.
14. Smith D, Bullock A, Catalona W: Racial differences in operating characteristics of prostate cancer screening tests. J Urol 1997; 158: 1861-1866. (Pubitemid 27433167)
15. Morton RA Jr: Racial differences in adeno-carcinoma of the prostate in North American men. Urolog y 1994; 44: 637-645.
16. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD: A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2005; 35: 9-17.
17. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165:1146-1151. (Pubitemid 32210224)